Epidemiology of Venous Thromboembolism and Treatment Pattern of Oral Anticoagulation in Korea, 2009–2016: a Nationwide Study Based on the National Health Insurance Service Database
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
BACKGROUND: The annual incidence of venous thromboembolism (VTE) is increasing, and the treatment pattern of oral anticoagulants (OACs) has changed with introduction of new oral anticoagulants (NOACs). The aims of this study were to assess the annual incidence of VTE in a Korean population and the change of treatment pattern with availability of NOACs using a population-based database. METHODS: Using the Korean National Health Insurance Services database, we identified patients diagnosed with VTE between 2009 and 2016. The annual prevalence of VTE and clinical characteristics and treatment pattern were investigated. The annual incidence of VTE was calculated using direct and indirect methods using the estimated Korean population in 2009 as the reference. RESULTS: The annual incidence of VTE in Korean has increased yearly from 23.9 per 100,000 in 2009 to 42.2 in 2016. The overall rate of OAC prescription for VTE treatment increased from 55.9% to 68% in the same time period. The rate of initiation of NOAC treatment greatly increased, particularly from 2013 onwards, with a 20-fold increase from 2009 to 2016 (2.1% vs. 54.3%). CONCLUSIONS: The annual incidence of VTE in Korea increased by almost two-fold from 2009 to 2016. The rate of initiation of NOAC treatment has increased substantially since 2013, and these agents have surpassed VKAs as the anticoagulant of choice for VTE. This temporal pattern of OAC prescription is consistent with the current clinical guidelines, which indicate NOACs over the warfarin in patients with VTE.
Abstract
BACKGROUND: The annual incidence of venous thromboembolism (VTE) is increasing, and the treatment pattern of oral anticoagulants (OACs) has changed with introduction of new oral anticoagulants (NOACs). The aims of this study were to assess the annual incidence of VTE in a Korean population and the change of treatment pattern with availability of NOACs using a population-based database. METHODS: Using the Korean National Health Insurance Services database, we identified patients diagnosed with VTE between 2009 and 2016. The annual prevalence of VTE and clinical characteristics and treatment pattern were investigated. The annual incidence of VTE was calculated using direct and indirect methods using the estimated Korean population in 2009 as the reference. RESULTS: The annual incidence of VTE in Korean has increased yearly from 23.9 per 100,000 in 2009 to 42.2 in 2016. The overall rate of OAC prescription for VTE treatment increased from 55.9% to 68% in the same time period. The rate of initiation of NOAC treatment greatly increased, particularly from 2013 onwards, with a 20-fold increase from 2009 to 2016 (2.1% vs. 54.3%). CONCLUSIONS: The annual incidence of VTE in Korea increased by almost two-fold from 2009 to 2016. The rate of initiation of NOAC treatment has increased substantially since 2013, and these agents have surpassed VKAs as the anticoagulant of choice for VTE. This temporal pattern of OAC prescription is consistent with the current clinical guidelines, which indicate NOACs over the warfarin in patients with VTE.
참고문헌 (31)
- Silverstein MD, "Trends in the incidence of deep vein thrombosis and pulmonary embolism : a 25-year population-based study", Arch Intern Med, 158, pp.585~593 (1998)
- Tagalakis V, "Incidence of and mortality from venous thromboembolism in a real-world population : the Q-VTE Study Cohort", Am J Med, 126, pp.832~ (2013)
- White RH, "A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism", Arch Intern Med, 160, pp.2033~2041 (2000)
- Fernandez MM, "Review of the cost of venous thromboembolism", Clinicoecon Outcomes Res, 7, pp.451~462 (2015)
- Cheuk BL, "Epidemiology of venous thromboembolism in a Chinese population", Br J Surg, 91, pp.424~428 (2004)
- Jang MJ, "Incidence of venous thromboembolism in Korea : from the Health Insurance Review and Assessment Service database", J Thromb Haemost, 9, pp.85~91 (2011)
- Lee CH, "Incidence and cumulative recurrence rates of venous thromboembolism in the Taiwanese population", J Thromb Haemost, 8, pp.1515~1523 (2010)
- Yusuf HR, "Grosse SDCenters for Disease Control and Prevention (CDC). Venous thromboembolism in adult hospitalizations - United States, 2007-2009", MMWR Morb Mortal Wkly Rep, 61, pp.401~404 (2012)
- Wiener RS, "Time trends in pulmonary embolism in the United States : evidence of overdiagnosis", Arch Intern Med, 171, pp.831~837 (2011)
- Holst AG, "Risk factors for venous thromboembolism : results from the Copenhagen City Heart Study", Circulation, 121, pp.1896~1903 (2010)
- Moretti AM, "Epidemiology of pulmonary embolism in Apulia from analysis of current data", Monaldi Arch Chest Dis, 73, pp.18~24 (2010)
- Shiraev TP, "Trends in pulmonary embolism morbidity and mortality in Australia", Thromb Res, 132, pp.19~25 (2013)
- Vázquez FJ, "Incidence rate of symptomatic venous thromboembolic disease in patients from a medical care program in Buenos Aires, Argentina: a prospective cohort", Thromb J, 11, pp.16~ (2013)
- Law Y, "Epidemiological updates of venous thromboembolism in a Chinese population", Asian J Surg, 41, pp.176~182 (2018)
- Hald EM, "Venous thromboembolism increases the risk of atrial fibrillation: the Tromso study", J Am Heart Assoc, 3, pp.e000483~ (2014)
- Raskob GE, "Thrombosis : a major contributor to global disease burden", Arterioscler Thromb Vasc Biol, 34, pp.2363~2371 (2014)
- Hylek EM, "Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation", Circulation, 115, pp.2689~2696 (2007)
- Cho IY, "Using non-vitamin K oral anticoagulants in specific patient populations : a study of Korean cases", Ther Clin Risk Manag, 15, pp.1183~1206 (2019)
- Curtin LR, "Direct standardization(age-adjusted death rates)", Healthy People 2000 Stat Notes, pp.1~10 (1995)
- Tripepi G, "Stratification for confounding--part 2: direct and indirect standardization", Nephron Clin Pract, 116, pp.c322~c325 (2010)
- Severinsen MT, "Body height and sex-related differences in incidence of venous thromboembolism : a Danish follow-up study", Eur J Intern Med, 21, pp.268~272 (2010)
- Hong J, "Incidence of venous thromboembolism in Korea from 2009 to 2013", PLoS One, 13, pp.e0191897~ (2018)
- Bizien N, "Age is a major risk factor of venous thromboembolism(VTE)", Eur Respir J, 38, pp.3936~ (2011)
- 이재환, "Role of Echocardiography in Patients with Acute Pulmonary Thromboembolism", Journal of Cardiovascular Imaging, 16(1), pp.9~16 (2008), 한국심초음파학회
- Schuh T, "Age-dependency of prescribing patterns of oral anticoagulant drugs in Austria during 2011–2014", J Thromb Thrombolysis, 42, pp.447~451 (2016)
- Weitz JI, "Trends in prescribing oral anticoagulants in Canada, 2008–2014", Clin Ther, 37, pp.2506~2514 (2015)
- Loo SY, "Trends in the prescription of novel oral anticoagulants in UK primary care", Br J Clin Pharmacol, 83, pp.2096~2106 (2017)
- Schulman S, "Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis", Circulation, 129, pp.764~772 (2014)
- Prins MH, "Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism : a pooled analysis of the EINSTEIN-DVT and PE randomized studies", Thromb J, 11, pp.21~ (2013)
- Agnelli G, "Oral apixaban for the treatment of acute venous thromboembolism", N Engl J Med, 369, pp.799~808 (2013)
- Büller HR, "Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism", N Engl J Med, 369, pp.1406~1415 (2013)